Combined Effects of Phytohemagglutinin and Staphylococcal Enterotoxin B on Deoxyribonucleic Acid Synthesis During Blast Transformation in Human Lymphocytes

Por Shambaugh, George E., Blumenschein, George R.
Publicado em 1974

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

Por Blumenschein, George R., Mills, Gordon B., Gonzalez-Angulo, Ana M.
Publicado em 2012

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Por Raghav, Kanwal Pratap Singh, Gonzalez-Angulo, Ana Maria, Blumenschein, George R.
Publicado no Transl Lung Cancer Res (2012)

Endobronchial Metastases in Breast Carcinoma

Por Krutchik, Allan N., Tashima, Charles K., Buzdar, Aman U., Blumenschein, George R.
Publicado em 1978

Mesothelin expression and survival outcomes in triple receptor negative breast cancer

Por Parinyanitikul, Napa, Blumenschein, George R., Wu, Yun, Lei, Xiudong, Chavez-MacGregor, Mariana, Smart, Melody, Gonzalez-Angulo, Ana Maria
Publicado em 2013

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

Por Blumenschein, George R., Paulus, Rebecca, Curran, Walter J., Robert, Francisco, Fossella, Frank, Werner-Wasik, Maria, Herbst, Roy S., Doescher, Philip O., Choy, Hak, Komaki, Ritsuko
Publicado em 2011

EGFR Expression and Survival in Patients Given Cetuximab and Chemoradiation for Stage III Non-Small Cell Lung Cancer: A Secondary Analysis of RTOG 0324

Por Komaki, Ritsuko, Paulus, Rebecca, Blumenschein, George R, Curran, Walter J., Robert, Francisco, Thariat, Juliette, Werner-Wasik, Maria, Choy, Hak, Hirsch, Fred R., Ang, K. Kian
Publicado em 2014

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

Por Heath, Elisabeth I., Blumenschein, George R., Cohen, Roger B., LoRusso, Patricia M., LoConte, Noelle K., Kim, Sindy T., Ruiz-Garcia, Ana, Chao, Richard C., Wilding, George
Publicado em 2010

Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer

Por Komaki, Ritsuko, Allen, Pamela K., Wei, Xiong, Blumenschein, George R., Tang, Ximing, Lee, J. Jack, Welsh, James W., Wistuba, Ignacio I., Liu, Diane D., Hong, Waun Ki
Publicado no Int J Radiat Oncol Biol Phys (2015)

cMET and phospho-cMET protein levels in breast cancers and survival outcomes

Por Raghav, Kanwal P., Wang, Wenting, Liu, Shuying, Chavez-MacGregor, Mariana, Meng, Xiaolong, Hortobagyi, Gabriel N., Mills, Gordon B., Meric-Bernstam, Funda, Blumenschein, George R., Gonzalez-Angulo, Ana M.
Publicado em 2012

Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer

Por Komaki, Ritsuko, Wei, Xiong, Allen, Pamela K., Liao, Zhongxing, Milas, Luka, Cox, James D., O’Reilly, Michael S., Chang, Joe Y., McAleer, Mary Frances, Jeter, Melenda, Blumenschein, George R., Kies, Merrill S.
Publicado em 2011

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

Por Johnson, Faye M., Bekele, B. Nebiyou, Feng, Lei, Wistuba, Ignacio, Tang, Xi Ming, Tran, Hai T., Erasmus, Jeremy J., Hwang, Li-Ling, Takebe, Naoko, Blumenschein, George R., Lippman, Scott M., Stewart, David J.
Publicado em 2010

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

Por Gold, Kathryn A., Lee, J. Jack, Harun, Nusrat, Tang, Ximing, Price, Justina, Kawedia, Jitesh D., Tran, Hai T., Erasmus, Jeremy J., Blumenschein, George R., William, William N., Wistuba, Ignacio I., Johnson, Faye M.
Publicado em 2014

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Por Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R., Glisson, Bonnie S., Kies, Merrill S., Tsimberidou, Apostolia M., Wheler, Jennifer J., Zinner, Ralph G., Hong, David S., Kurzrock, Razelle, Piha-Paul, Sarina A.
Publicado no Oncotarget (2016)

Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

Por Tsao, Anne S., Liu, Suyu, Lee, J. Jack, Alden, Christine M., Blumenschein, George R., Herbst, Roy, Davis, Suzanne E., Kim, Edward, Lippman, Scott, Heymach, John, Tran, Hai, Tang, XiMing, Wistuba, Ignacio, Hong, Waun Ki
Publicado no J Thorac Oncol (2013)

Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer

Por Gonzalez-Angulo, Ana M., Chen, Huiqin, Karuturi, Meghan S., Chavez-MacGregor, Mariana, Tsavachidis, Spyrus, Meric-Bernstam, Funda, Do, Kim-Anh, Hortobagyi, Gabriel N., Thompson, Patricia A., Mills, Gordon B., Bondy, Melissa L., Blumenschein, George R.
Publicado em 2012

Feasibility of Image-Guided Transthoracic Core Needle Biopsy in the BATTLE Lung Trial

Por Tam, Alda L., Kim, Edward S., Lee, J. Jack, Ensor, Joe E., Hicks, Marshall E., Tang, Ximing, Blumenschein, George R., Alden, Christine M., Erasmus, Jeremy J., Tsao, Anne, Lippman, Scott M., Hong, Waun K., Wistuba, Ignacio I., Gupta, Sanjay
Publicado em 2013

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

Por Said, Rabih, Ye, Yang, Falchook, Gerald Steven, Janku, Filip, Naing, Aung, Zinner, Ralph, Blumenschein, George R., Fu, Siqing, Hong, David S., Piha-Paul, Sarina Anne, Wheler, Jennifer J., Kurzrock, Razelle, Palmer, Gary A., Aldape, Kenneth, Hess, Kenneth R., Tsimberidou, Apostolia Maria
Publicado no Oncotarget (2014)

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Por Spigel, David R., Ervin, Thomas J., Ramlau, Rodryg A., Daniel, Davey B., Goldschmidt, Jerome H., Blumenschein, George R., Krzakowski, Maciej J., Robinet, Gilles, Godbert, Benoit, Barlesi, Fabrice, Govindan, Ramaswamy, Patel, Taral, Orlov, Sergey V., Wertheim, Michael S., Yu, Wei, Zha, Jiping, Yauch, Robert L., Patel, Premal H., Phan, See-Chun, Peterson, Amy C.
Publicado no J Clin Oncol (2013)

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Por Ihle, Nathan T., Byers, Lauren A., Kim, Edward S., Saintigny, Pierre, Lee, J. Jack, Blumenschein, George R., Tsao, Anne, Liu, Suyu, Larsen, Jill E., Wang, Jing, Diao, Lixia, Coombes, Kevin R., Chen, Lu, Zhang, Shuxing, Abdelmelek, Mena F., Tang, Ximing, Papadimitrakopoulou, Vassiliki, Minna, John D., Lippman, Scott M., Hong, Waun K., Herbst, Roy S., Wistuba, Ignacio I., Heymach, John V., Powis, Garth
Publicado em 2012